Prelude Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Prelude Therapeutics Incorporated

10/05/2022 17:29

* Prelude Therapeutics Inc  PRLD.OQ  reported a quarterly
adjusted
loss of 63 cents​​ per share for the quarter ended in March. The
mean expectation of four analysts for the quarter was for a loss
of 65 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Prelude Therapeutics Inc's reported EPS for the quarter
was a
loss of 63 cents​.
    * The mean earnings estimate of analysts had risen by
about 5.8%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Prelude Therapeutics Inc shares had fallen by 42.0% this
quarter and lost 67.9% so far this year.
    * The company reported a quarterly loss of $29.47 million.
    * Wall Street's median 12-month price target for Prelude
Therapeutics Inc is $15.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 10 at 04:29 p.m.  ​All
figures in US dollars unless otherwise stated